← Back to Search

Direct Thrombin Inhibitor

Dabigatran Etexilate Mesylate for Acute Pancreatitis

Phase 1
Waitlist Available
Led By Yan Bi, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

This study is evaluating whether a drug called dabigatran may help treat acute pancreatitis.

Eligible Conditions
  • Acute Pancreatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events

Trial Design

2Treatment groups
Active Control
Group I: Dabigatran Etexilate MesylateActive Control2 Interventions
Dabigatran 150mg BID for 3 days
Group II: Standard of CareActive Control1 Intervention
Standard treatment for acute pancreatitis

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,212 Previous Clinical Trials
3,767,036 Total Patients Enrolled
2 Trials studying Acute Pancreatitis
111 Patients Enrolled for Acute Pancreatitis
Yan Bi, MD, PhDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
1 Previous Clinical Trials
324 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025